Valuation: Assembly Biosciences, Inc.

Market Cap 70Cr 60Cr 56Cr 51Cr 96Cr 6.7TCr 98Cr 662.86Cr 258.49Cr 3.36TCr 262.84Cr 257.12Cr 11TCr P/E 2026 *
-60x
P/E 2027 * -11.8x
Enterprise Value 70Cr 60Cr 56Cr 51Cr 96Cr 6.7TCr 98Cr 662.86Cr 258.49Cr 3.36TCr 262.84Cr 257.12Cr 11TCr EV / Sales 2026 *
11.3x
EV / Sales 2027 * 21.7x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
1 day+2.54%
1 week+4.34%
Current month+36.92%
1 month+29.88%
3 months+29.74%
6 months+19.58%
Current year+1.09%
1 week 29.83
Extreme 29.83
35.62
1 month 24.5
Extreme 24.5
35.62
Current year 21.8
Extreme 21.795
35.62
1 year 20.23
Extreme 20.23
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
47.28
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Free

Director

8,000 0.0514%
29/03/26 Free

Chief Technology Officer

26,000 0.1671%
08/08/25 BuyCompany 45,91,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
+2.54%+4.34%+29.01%+221.91% 70Cr
+1.09%+5.26%+4.44%+26.03% 5.16TCr
-1.07%+2.82%+474.18%+601.24% 4.49TCr
+1.47%+9.79%+40.15%+21.21% 4.28TCr
+1.44%+7.77%+19.27%+90.94% 4.26TCr
-0.93%-4.33%+17.87%+51.96% 3.18TCr
+1.32%+7.30%+36.93%+152.36% 1.73TCr
-0.60%+1.93% - - 1.66TCr
+0.03%+3.41%+7.12%+35.49% 1.48TCr
+1.28%+5.41%+91.01%+46.93% 1.41TCr
Average +0.66%+4.38%+80.00%+138.67% 2.77TCr
Weighted average by Cap. +0.49%+4.71%+102.37%+148.72%

Financials

2026 *2027 *
Net sales 6.2Cr 5.31Cr 4.97Cr 4.55Cr 8.54Cr 593.4Cr 8.65Cr 59Cr 23Cr 298.09Cr 23Cr 23Cr 985.96Cr 3.22Cr 2.76Cr 2.58Cr 2.37Cr 4.44Cr 308.57Cr 4.5Cr 31Cr 12Cr 155.01Cr 12Cr 12Cr 512.7Cr
Net income -1.06Cr -90.9L -85.05L -77.86L -1.46Cr -101.53Cr -1.48Cr -10Cr -3.92Cr -51Cr -3.98Cr -3.9Cr -168.7Cr -6.03Cr -5.16Cr -4.83Cr -4.42Cr -8.3Cr -576.6Cr -8.41Cr -57Cr -22Cr -289.65Cr -23Cr -22Cr -958.05Cr
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
21/26/21 $34.38 +2.54% 3,41,539
20/26/20 $33.53 -0.92% 2,15,023
19/26/19 $33.84 +5.32% 3,84,565
18/26/18 $32.13 +7.06% 4,84,813
17/26/17 $30.01 -8.92% 3,04,523
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.38USD
Average target price
50.00USD
Spread / Average Target
+45.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock